Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07215663
PHASE1

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

Sponsor: Candid Therapeutics

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Systemic Lupus Erythematosus

Official title: A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Systemic Lupus Erythematosus

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

47

Start Date

2025-09-04

Completion Date

2028-04

Last Updated

2025-11-17

Healthy Volunteers

No

Interventions

DRUG

Cizutamig

Cizutamig will be dosed according to the protocol

Locations (1)

Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

Beijing, China